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Abstract
Background: The aim of the study was to investigate whether p503S, p504S and p510S gene
expression in peripheral-blood be useful as a diagnostic or prognostic marker of prostatic cancer.
Methods: Circulating cells were identified by reverse transcription-polymerase chain reaction
(RT-PCR) to detect p503S, p504S and p510S mRNA in peripheral blood (PB) from 11 patients with
treated prostatic carcinoma (CaP), 11 with newly-diagnosed untreated CaP and 20 with benign
prostatic hyperplasia (BPH) (controls).
Results: RT-PCR amplified P503S in 7 of 11 untreated and 2 of 11 treated patients with CaP and
5 of 20 with BPH; p504S in 7 of 11 untreated and in 9 of 11 treated patients with CaP and 11 of 20
with BPH; whereas it amplified p510S in all subjects with CaP and in 15 of 20 with BPH.
Conclusion: These findings suggest that the investigated genes are poorly specific and probably of
little use as diagnostic or prognostic prostatic markers in peripheral blood for monitoring disease
progression and recurrence.
Background
Microarray approaches have identified three prostate tis-
sue and cancer-prostate-specific genes: p503S, a 241-
amino acid protein that encodes human tetraspan NET-1,
a member of the tetraspanin/TM4SF family, involved in
cancer metastasis) [1], P504S, also referred to as the
AMACR gene, encodes human α-methylacyl-CoA race-
mase, a 382-amino acid protein involved in the conver-
sion of R-stereoisomers of branched-chain fatty acids to S-
stereoisomers [2-6] and p510S, identified as the human
ABC transporter MOAT-B [7]. All these genes are overex-
pressed in prostate tumor or normal prostate tissue or
both and are considered clinical biomarkers of prostate
cancer (CaP)[8]. The immune response against AMACR
has been used as a serum biomarker for CaP [9,10] and
the quantification of AMACR transcripts in prostatic secre-
tions shown to be predictive of CaP [11].
Attempts to detect AMACR in circulation have been disap-
pointing and no molecular studies have yet sought p503S
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and p510S circulating cells by reverse transcriptase-
polymerase chain reaction (RT-PCR) assay of peripheral
blood (PB) from patients with CaP.
The aim of this study was to investigate whether p503S,
p504S and p510S genes are diagnostic or prognostic pros-
tate-specific markers for monitoring disease progression
and recurrence. Extending our previous research investi-
gating biomarkers that are clinically important to distin-
guish patients with prostate cancer at risk for early relapse
from patients in clinical remission [12-14], in this study,
we analyzed by RT-PCR assays p503S, p504S and p510S
gene markers in PB from 42 patients with treated or
untreated CaP and with benign prostatic hyperplasia
(BPH) (controls).
Methods
Patients and control tissue specimens
The 42 participants included in this study were consecu-
tively selected from patients treated at the Department of
Urology "U. Bracci", University of Rome "La Sapienza".
We studied three clinical groups. The first group com-
prised 11 patients with CaP (mean age at diagnosis 68.9
years; range 45–89) who underwent androgen ablation
(AA) followed by retropubic radical prostatectomy (RP)
and bilateral lymphadenectomy between January 1997
and December 1999. Tumors were graded using the
Gleason system for histologic grading of CaP: two tumors
were Gleason score sum 4, 7 Gleason sum 7 and 2
Gleason sum 8. Tumors were then evaluated clinico-path-
ologically using the tumor-node metastatic (TNM) staging
system 2002: 7 tumors were organ-confined diseases
(pT2) and 4 were extra-prostatic diseases (pT3). Follow-
up after treatment ranged from 3–84 months (mean, 27
months). At the time of venipuncture for PB, we distin-
guished two subgroups: patients who responded to the
first 24 months of treatment without clinical progression;
and AA resistant patients who received neoadjuvant
androgen deprivation therapy because recurrent disease
developed within 24 months after RP. We defined recur-
rence by serum PSA levels, transrectal ultrasound (TRUS)
and computed tomographic (CT) scan. Men were consid-
ered disease free after RP if they had serum PSA levels less
than 0.1 ng/ml. The second subgroup comprised 11
patients with elevated serum PSA levels (more than 4.0
ng/ml), who had received a diagnosis of CaP based on
TRUS-guided-prostate biopsy (1 tumor was Gleason sum
6 and 10 were Gleason sum 7). All 11 patients had organ-
confined disease: 4 were pT1 and 7, pT2. In patients
treated for CaP, PB samples were obtained 27 to 84
months (mean 55 months) after treatment ended; in
patients who had received a diagnosis of CaP based on
clinical and biochemical evidence of malignancy, PB sam-
ples were obtained before biopsy and before treatment
began. The third group (control group) comprised 20
men 50 years of age or older (mean age 58.7 years; range
45–79) with no known malignancy, with a histologic
diagnosis of BPH in tissue obtained by fine-needle biopsy
of the prostatic glands and on conventional clinical data
(serum PSA levels less than 4.0 ng/ml, and digital rectal
examination and TRUS negative for CaP). The control
group also included a PB sample from a patient who
underwent radical cystectomy for bladder cancer (G3T1)
and 6 neoplastic and non neoplastic prostatic tissues; 6
tissues from various organs (adrenal gland, heart, myo-
metrium and uterine cervix); and 6 prostatic (SV48,
LS147D, SCOV 3 and MCF7) and non prostatic cell lines
(PC3 and LNCaP).
Reverse-transcription polymerase-chain-reaction (RT-
PCR)
Total RNA was extracted from whole blood cells and cell
lines using the technique previously described [12-15].
Total RNA from frozen tissue was extracted using the pro-
tocol developed by Ambion, and detailed in the RNA iso-
lation Kit (Ambion Inc., U.S.A). cDNA (250 ng) from each
sample was amplified by PCR using the following prim-
ers: sense, 5'TGCCCTCGTGACGTTCTTCT3' and antisense
5'TCTTTCTTGATGGCAGGCACTAC3' of P503, 136 bp
(GeneBank accession number AF065388 (16) using 35
cycles (94°C for 30", 60°C for 30" and 72°C for 60 sec);
sense 5'AAATGGTTATCATTAGGGCTTTTGA3' and anti-
sense 5'TTCCTTTTTCACTAGAACCCATTCA3' of P504S,
149 bp (GeneBank accession number 4204097 [17] using
35 cycles (94°C for 30", 55°C for 30" and 72°C for 60
sec); sense
5'TTGAACAGCTACTACGGTCAATGTATT3'and antisense
5' GCAGAGAGCAACCGATGTTTT3' of P510S, 96 bp
Analysis of gene expression levels of p503S, p504S and p510S  by RT-PCR using β-actin yielded a 740 base-pair band as  internal control, in whole blood from 11 patients after radical  prostatectomy and androgen ablation (lanes 1 to 11); nega- tive control, no RNA (lane 12); positive control (LNCaP cell  line) (lane13); MW (molecular weight) Figure 1
Analysis of gene expression levels of p503S, p504S and p510S 
by RT-PCR using β-actin yielded a 740 base-pair band as 
internal control, in whole blood from 11 patients after radical 
prostatectomy and androgen ablation (lanes 1 to 11); nega-
tive control, no RNA (lane 12); positive control (LNCaP cell 
line) (lane13); MW (molecular weight).BMC Cancer 2005, 5:111 http://www.biomedcentral.com/1471-2407/5/111
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Table 1: RT-PCR assay in peripheral blood, in different tissues and cell lines.
SAMPLES RT-PCR P503S P504S P510S
PB N o  ( % )N o  ( % )N o  ( % )
group 1
AA and RP (n = 11) positive 7 (63.63) 7 (63.63) 11 (100)
negative 4(36.36) 4(36.36) 0
group 2
Pca in prostate biopsy (n = 11) positive 2 (18.18) 9 (81.81) 11 (100)
negative 9 (81.81) 2 (18.18) 0
group 3
BPH in prostate biopsy (n = 20) positive 5 (25) 11 (55) 15 (75)
negative 15 (75) 9 (45) 5 (25)
Frozen tissues
Neoplastic and non neoplastic positive 4 (66.66) 4 (66.66) 5 (83.83)
prostate tissues (n = 6) negative 2 (33.33) 2 (33.33) 1 (16.16)
Non prostatic tissues (n = 6) positive 6 (100) 1(16.66) 2 (33,33)
negative 0 5 (83.33) 4 (66.66)
Cell lines (n = 6)
prostatic (n = 2) positive 2 (100) 2 (100) 2 (100)
negative 0 0 0
non prostatic (n = 4) positive 4 (100) 2 (50) 2 (50)
negative 0 2 (50) 2 (50)
PB = peripheral blood
RT = radical prostatectomy
AA = androgen ablation
Table 2: p503S, p504S and p510S positive cells in peripheral blood of patients with prostate cancer (CaP) in relation to Gleason score 
and TNM stage.
P503S+ P504S+ P510S+
Group 1 (treated CaP) No No No
Total (n = 11) patients (%) patients (%) patients (%)
subtype 1 without recurrence (n = 
5)
2 (40) 2 (40) 5 (100)
subtype 2 with recurrence (n = 6) 5 (83) 5 (83) 6 (100)
Gleason score
4–7 (n = 9) 4 (44.44) 6 (66.66) 9 (100)
8 (n = 2) 2 (100) 2 (100) 2 (100)
TNM
Organ-confined disease (n = 7)
T2 N0 M0 (n = 7) 4 (57.14) 5 (71.42) 7 (100)
Extraprostatic disease (n = 4)
T3 N0 M0 (n = 2) 1 (50) 1 (50) 2 (100)
T3 N1M0 and T3 N2M0 (n = 2) 2 (100) 1 (50) 2 (100)BMC Cancer 2005, 5:111 http://www.biomedcentral.com/1471-2407/5/111
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(GeneBank accession number AF071202 [18] using 35
cycles (94°C for 30", 57°C for 30" and 72°C for 60 sec)
by Platinum Taq DNA polymerase (Gibco BRL), accord-
ing to the manufacturer's protocols. The integrity of RNA
was checked in a preliminary PCR reaction for a human β-
actin 743 base-pair (bp) fragment [19]. Each RT-PCR
experiment included a non retrotranscribed sample as a
negative control and c-DNA from LNCaP cell lines as a
positive control. PCR-amplified P510S sequence specifi-
city was checked by direct sequencing of the amplified
product by the automated DNA sequencer A.L.F. (Phar-
macia, Freiburg, Germany). The sequencing reaction was
run on an Abby Applied 377 Sequencer (Applied Biosys-
tems). Band identity was verified by comparison with the
genomic and cDNA P510S sequences at the GeneBank
using the BLAST program.
Results
RT- PCR analysis amplified p5103S-, p504S- and p510S-
mRNA in PB from nearly all patients who underwent AA
and RP, who had recurrent disease and p503S and p504S
in only 2 (40%) of the 5 patients without recurrence (Fig.
1; Table 1). Comparing the RT-PCR findings with the his-
tological Gleason scores we found p503S- and p504S-pos-
itive cells in a higher percentage of patients with higher-
grade Gleason scores than lower-grade scores. P503S were
more often expressed in extraprostatic disease (pT3N1
and pT3N2) and p504S in organ-confined disease
(pT2N0). The p510S gene was amplified in all patients
regardless of the clinical subgroup (Table 2).
Two samples from 11 untreated patients with biopsy-
proven CaP contained p503S mRNA. This gene was
expressed significantly less frequently than p504S and
p510S (18% vs 81 and 100% (P <.01, by chi-square test)
(Fig. 2; Table 1). PB from the control patient with non
prostate malignancies, who underwent radical cystectomy
for transitional-cell carcinoma (G3T1), contained p504S-
and p510S-but no p503S-positive cells (Fig. 2, lane 12).
Nearly all untreated patients with Gleason score 6–7
tumors and organ-confined disease had p504S- and
p510S-positive cells, whereas only 2 of the 11 patients
had p503S-positive cells. p503S-positive cells were
detectable in patients with stage pT2 and undetectable in
those with stage pT1 disease. p510S-positive cells were
expressed in similar percentages of patients with pT1 and
pT2 disease (Table 2).
In PB samples from the control group (BPH), PCR ampli-
fied more p504S- and p510S- than p503S-positive cells
(55 and 75% vs 25%) (Fig. 3). Nearly all the prostatic and
non prostatic-tissues and cell lines used as controls
expressed p503S-, p504S-, and p510S-mRNA (Table 1)
(Fig. 4). DNA sequencing of the amplified 96 bp fragment
confirmed the specificity of these primers for the p510S
gene (Fig. 5).
Group 2 (untreated CaP)
Total (n = 11)
Gleason score
6–7 (n = 11) 2 (18.18) 9 (81.81) 11 (100)
TNM
Organ-confined disease (n = 11)
T1 (n = 4) 0 3 (75 4 (100)
T2 (n = 7) 2 (28.6) 6 (85.7) 7 (100)
Table 2: p503S, p504S and p510S positive cells in peripheral blood of patients with prostate cancer (CaP) in relation to Gleason score 
and TNM stage. (Continued)
Analysis of gene expression levels of p503S, p504S and p510S  by RT-PCR using β-actin yielded a 740 base-pair band as  internal control, in whole blood from 11 patients with CaP  after biopsy (lanes 1 to 11) and one patient with transitional  cell carcinoma of the bladder (lane 12) as control Figure 2
Analysis of gene expression levels of p503S, p504S and p510S 
by RT-PCR using β-actin yielded a 740 base-pair band as 
internal control, in whole blood from 11 patients with CaP 
after biopsy (lanes 1 to 11) and one patient with transitional 
cell carcinoma of the bladder (lane 12) as control. Negative 
control (no RNA) (lane 13); positive control (LNCaP cell 
line) (lane 14); MW (molecular weight).BMC Cancer 2005, 5:111 http://www.biomedcentral.com/1471-2407/5/111
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Discussion
These findings argue against the usefulness of the p503S,
p504S and p510S genes as diagnostic and probably
against their usefulness as prognostic prostate-specific
markers for monitoring disease progression and recur-
rence in PB from patients with CaP. Our findings obtained
by RT-PCR assay contrast with Zelie et al [11] et al who
found the RT-PCR-AMACR test non-invasive and useful in
predicting the presence of CaP in prostatic secretions.
When we compared our findings for p503S, p504S and
p510S with our earlier study investigating prostatic spe-
cific antigen (PSA) [3], as potential markers for prostate
tumors, all these three genes were more frequently
expressed than PSA in PB from patients with treated CaP
(63%, 63% and 100% vs 18%) and untreated CaP (18%,
81% and 100% vs 9%) and in PB from BPH (25%, 55%
and 75% vs 0). In benign and malignant prostate tissue,
p510S was more strongly expressed than PSA, or p503S
and p504S (100% vs 66% vs 66%), whereas in prostatic
cell lines, PSA and p503S, p504S and p510S were simi-
larly expressed (100%). In non prostatic tissue and cell
lines, PSA was not expressed; in contrast, in non prostatic
samples and cell lines, p503S was more expressed than
p510S and p504S (100% vs 33% vs 16%) and cell lines
(100% vs 50% vs 50%). Hence, the increased expression
of PSA mRNA in prostate tissue suggests that PSA is more
specific than p503S, p504S and p510S as a marker of can-
cer progression and dissemination.
The ubiquitous presence of p503S, p504S and p510S in
PB of patients with BPH, in non prostatic tissue and cell
lines therefore argues against their potential value as
biomarkers of prostate disease. Compared with PSA [13],
none of the three newly-identified putative CaP markers
we studied were sufficiently sensitive or specific to distin-
guish patients in complete clinical remission from
patients with occult metastatic disease at high-risk for
relapse. The numerous false-positive findings in our assay
and the reported presence of p503S, p504S and p510S in
normal hematopoietic tissues also from patients without
prostate malignancies [20], could depend on illegitimate
expression of gene transcripts. This question awaits an
answer from studies designed to investigate the whole
p503S, p504S and p510S gene sequence. For RT-PCR
analysis of PB cells in this study we used primers for three
new putative genes (p503S, p504S, and p510S) whose
prostate cancer specificity has already been confirmed by
Northern blot, real-time PCR and immunohistochemical
assay on prostatic tissue [3-8]. Although AMACR may be
potentially useful as a tissue biomarker for prostate cancer
[3,4], the limitations of this assay make it impossible to
use an autoimmune response against AMACR as a means
of detecting this antigen in the serum [10]. Nor did a
novel approach to predict the presence of CaP from pros-
tatic secretions prove predictive of CaP [9]. Whether these
new markers have potential clinical utility as sensitive and
specific indicators of CaP progression therefore warrants
further research using quantitative RT-PCR technique to
study the entire gene sequences.
Conclusion
We provide the first evidence of the ubiquitous presence
of p503S, p504S and p510S in PB of patients with BPH, in
non prostatic tissue and cell lines. These findings suggest
that the investigated genes are poorly specific and proba-
bly of little use as diagnostic or prognostic prostatic
markers in peripheral blood for monitoring disease pro-
gression and recurrence.
Analysis of gene expression levels of p503S, p504S and p510S  by RT-PCR using β-actin yielded a 740 base-pair band as  internal control in whole blood from 17 of 20 patients with  benign prostatic disease (BPH) Figure 3
Analysis of gene expression levels of p503S, p504S and p510S 
by RT-PCR using β-actin yielded a 740 base-pair band as 
internal control in whole blood from 17 of 20 patients with 
benign prostatic disease (BPH).
Analysis of gene expression levels of p503S, p504S and p510S  by RT-PCR using β-actin yielded a 740 base-pair band as  internal control in frozen benign (lanes 1, 3, and 6) and neo- plastic (lanes 2, 4, and 5) prostatic tissue; non prostatic tissue  (adrenal gland (lane 7); heart (lanes 8 to 10); myometrium  (lane 11); uterine cervix (lane 12) and human cell lines: SV48  (lane 13); LS147D (lane 14); SCOV 3 (lane 15); MCF7 (lane  16); PC3 (lane 17); and LNCaP (lane 18) Figure 4
Analysis of gene expression levels of p503S, p504S and p510S 
by RT-PCR using β-actin yielded a 740 base-pair band as 
internal control in frozen benign (lanes 1, 3, and 6) and neo-
plastic (lanes 2, 4, and 5) prostatic tissue; non prostatic tissue 
(adrenal gland (lane 7); heart (lanes 8 to 10); myometrium 
(lane 11); uterine cervix (lane 12) and human cell lines: SV48 
(lane 13); LS147D (lane 14); SCOV 3 (lane 15); MCF7 (lane 
16); PC3 (lane 17); and LNCaP (lane 18). Negative control no 
RNA (lane 19); MW (molecular weight).BMC Cancer 2005, 5:111 http://www.biomedcentral.com/1471-2407/5/111
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